At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 34 enrolled
Drug / intervention
Rucaparibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy With Rucaparib
In Brief
A Phase 3 clinical trial evaluating Rucaparib for Metastatic Castration-Resistant Prostate Cancer and 5 related conditions. Completed, enrolled 34 participants across 25 sites in 6 countries.
Detailed Summary
This protocol is designed to provide participants currently benefiting from rucaparib treatment in a Clovis-sponsored clinical study with continued access to treatment for as long as they continue to benefit. Participants in long-term follow-up (LTFU) in a parent study may also enroll in this study for continued data collection, as applicable based on parent study objectives.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Castration-Resistant Prostate Cancer, Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Other Solid Tumor
CountriesCanada, Israel, Italy, Poland, Russia, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartMar 2021
Primary CompletionMar 2023
TodayJul 2026
First PostedDec 21, 2020
Enrollment StartMar 22, 2021
Primary CompletionMar 8, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.5 years ago
Interventions
Rucaparibdrug
Rucaparib will be administered daily.